

Request Information Permalink

FEM₁B INHIBITORS

Tech ID: 32345 / UC Case 2021-139-0

PATENT STATUS

Country	Туре	Number	Dated	Case
Mexico	Published Application	TO COME	04/11/2024	2021-139
China	Published Application	117794533	03/29/2024	2021-139
Australia	Published Application	WO 2022/266321	12/22/2022	2021-139
Brazil	Published Application	WO 2022/266321	12/22/2022	2021-139
Canada	Published Application	WO 2022/266321	12/22/2022	2021-139
European Patent Office	Published Application	WO 2022/266321	12/22/2022	2021-139
Israel	Published Application	WO 2022/266321	12/22/2022	2021-139
India	Published Application	WO 2022/266321	12/22/2022	2021-139
Japan	Published Application	WO 2022/266321	12/22/2022	2021-139
Rep Of Korea	Published Application	WO 2022/266321	12/22/2022	2021-139
Russian Federation	Published Application	WO 2022/266321	12/22/2022	2021-139
Patent Cooperation Treaty	Published Application	WO 2022/266321	12/22/2022	2021-139

Additional Patent Pending

BRIEF DESCRIPTION

UC Berkeley researchers have discovered novel, specific Fem1b inhibitors. Fem1b is essential in lymphoma and lung cancer cells. Fem1b inhibition could be beneficial in cancer, metabolic disease, obesity, diabetes and other diseases.

SUGGESTED USES

>> therapeutics

ADDITIONAL TECHNOLOGIES BY THESE INVENTORS

- ▶ Plasmid Materials
- ▶ Ubiquitin Materials

CONTACT

Craig K. Kennedy craig.kennedy@berkeley.edu tel:



INVENTORS

» Rape, Michael

OTHER INFORMATION

CATEGORIZED AS

- » Medical
 - » Disease: Cancer
 - » Disease: Respiratory and

Pulmonary System

RELATED CASES

2021-139-0



University of California, Berkeley Office of Technology Licensing
2150 Shattuck Avenue, Suite 510, Berkeley,CA 94704

Tel: 510.643.7201 | Fax: 510.642.4566

ipira.berkeley.edu/ | otl-feedback@lists.berkeley.edu

© 2022 - 2024, The Regents of the University of California

Terms of use | Privacy Notice